Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mayo Clinic Researchers Discover Genetic Markers for Alcoholism Recovery

05.11.2014

In an international study, Mayo Clinic researchers and collaborators have identified genetic markers that may help in identifying individuals who could benefit from the alcoholism treatment drug acamprosate. The findings, published in the journal Translational Psychiatry, show that patients carrying these genetic variants have longer periods of abstinence during the first three months of acamprosate treatment.

Acamprosate is a commonly prescribed drug used to aid patients in recovery from alcoholism. Mayo researchers studied the association between variation in candidate genes and the length of sobriety in alcohol-dependent patients treated with acamprosate in community-based programs.

They found that, when other environmental and physiological factors were considered, patients with the common allele of the genetic variant rs2058878 located in the GRIN2B gene, stayed sober more days than those with a variant allele of the same polymorphism. This finding was replicated in a sample of alcohol-dependent patients treated with acamprosate in a study conducted by collaborators from Germany.

“This association finding is a first step towards development of a pharmacogenetic test allowing physicians to choose appropriate treatment for specific subgroups of alcohol-dependent patients,” says Victor Karpyak, M.D., Ph.D., Mayo Clinic psychiatrist and lead author of the article. “We believe that individualized treatment selection will eliminate the need for trial-and-error approaches and improve treatment efficacy in patients with alcohol use disorders.”

The Mayo findings support evidence implicating an important role of the N-Methyl-D-aspartate (NMDA) receptors in the treatment effects of acamprosate. The researchers say more studies are needed to determine potential importance of identified genetic variants in the longer-term effects of acamprosate, as well as the molecular and physiological mechanisms behind the drug’s action.

The study was funded in part by the Mayo Clinic Center for Individualized Medicine; the SC Johnson Genomics of Addiction Program at Mayo Clinic; the National Institutes of Health; the National Center for Advancing Translational Sciences; the National Genome Research Network of the German Federal Ministry of Education and Research; the Bundesministerium für Bildung und Forschung; and the Alfred Krupp von Bolen und Halbach-Stiftung (Foundation).

Other authors include J. M. Biernacka, Ph.D., Jennifer Geske, G.D. Jenkins, J.M. Cunningham, Ph.D., A.A. Leontovich, Ph.D., O.A. Abulseoud, M.D., Daniel Hall-Flavin, M.D., L.L. Loukianova, M.D., Ph.D., T.D. Schneekloth, M.D., M.K. Skime, Richard Weinshilboum, M.D., Mark Frye, M.D., and D.S. Choi, Ph.D., of Mayo Clinic; J. Ruegg, Karolinska Institutet; O. Kononenko, Uppsala University; J. Frank, M.D., M. Rietschel, M.D., F. Kiefer, M.D., and K. F. Mann, M.D., Mannheim-Heidelburg University; and M.M. Nöthen, M.D., University of Bonn.

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic  or http://newsnetwork.mayoclinic.org/ .

Bob Nellis | EurekAlert!
Further information:
http://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-discover-genetic-markers-for-alcoholism-recovery/

More articles from Life Sciences:

nachricht Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)

nachricht CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>